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Abstract
Background: Recombinant tissue plasminogen activator (tPA) is a thrombolytic widely used
clinically in the treatment of acute thrombotic disease such as ischemic stroke, myocardial
infarction, and deep venous thrombosis. This has led to much interest in tPA based lytic therapies
leading to laboratory based in-vitro  and  in-vivo  investigations using this drug. However, tPA
reconstituted in solution exhibits full activity for only 6–8 hours, according to the manufacturer.
Therefore, methods to store reconstituted tPA for long durations while maintaining activity would
be of assistance to laboratories using this enzyme.
Findings: In this work, the enzymatic activity of tPA stored at -80 C over time was measured, using
an ELISA technique that measured the amount of active tPA bound to plasminogen activator
inhibitor 1 (PAI-1) in a given sample. Sample of tPA solution mixed to a concentration of 1 (mg/ml)
were stored in cryogenic vials at -80 C for up to 7 years. For a given sample, aliquots were assayed
for tPA activity, and compared with a tPA standard to determine relative enzymatic activity. Results
are reported as means with standard errors, and 12 measurements were performed for each
sample age.
Conclusion: There was no decrease in tPA activity for samples stored up to 7 years. Such
cryogenic storage is a viable method for the preservation of tPA solution for laboratory
investigations of tPA-based lytic therapies.
Findings
Recombinant tissue plasminogen activator (tPA) is widely
to treat thrombotic disorders such as acute ischemic
stroke, deep venous thrombosis [1]. As a result, there is
much interest in optimizing lytic therapy using tPA in the
treatment of such disease [2]. Such optimization requires
substantial  in-vitro  and  in-vivo  [3] work. Therefore the
preservation of tPA for laboratory use in such studies is of
substantial interest to laboratories engaged in such
research.
Currently, tPA is available as a lyophilized powder from
the manufacturer (Genentech, San Francisco, CA).
According to the manufacturer, tPA can be used for 8
hours after reconstitution in sterile water at room temper-
ature; this is a short period of time for laboratory use.
Therefore, methods to store reconstituted tPA for long
durations while maintaining activity would be of assist-
ance to laboratories using this medication. In this work,
the enzymatic activity of tPA stored at -80 C over time was
measured.
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The tPA was obtained as a lyophilized powder and mixed
with sterile water to a concentration of 1 mg/mL (580,000
IU/ml), as per the manufacturer's instructions. Solution
samples were then stored at -80 C as 0.5–2 mL aliquots for
0.5 to 7.2 years in cryogenic vials. For activity measure-
ments, samples were thawed at room temperature and
diluted with 3% bovine serum albumin in tris buffered
saline to achieve a tPA concentration of 0.36, 0.73, 1.45,
2.9 or 3.6 (IU/ml). Three measurements at a given con-
centration were performed for each sample. The samples
were assayed for tPA activity using an ELISA technique
that measures active tPA using plasminogen activator
inhibitor 1 (PAI-1) (Human tPA Activity Assay, #IHT-
PAKT, Innovative Research, Novi, MI, USA). In this assay,
a biotinylated human PAI-1 antibody binds to the active
tPA in a given sample. Inactive tPA or tPA complexed with
another protein will not be detected.
Samples of the tPA solution were added to wells on the
microtiter plate after preparation with the PAI-1 antibody.
In addition, a tPA standard (provided with the kit) was
used to prepare a series of standard solutions of 0.345,
0.69, 1.38, 2.76, and 4.14 IU/ml. After incubation, anti-
human tPA antibody was added to the PAI-1 bound tPA.
Finally, anti-rabbit horseradish peroxidase (HRP) was
added, and 450 nm absorbance was determined (Spec-
traMax M5 dual-monochromator microplate reader,
Molecular Devices Corporation, Sunnyvale, CA) as a
measure of enzymatic activity. The intra-assay precision
was 9.8%, as stated by the manufacturer.
The absorbance values for the tPA standard solutions were
used to construct a calibration curve of absorbance vs tPA
concentration; fits to the data were performed using Soft-
max Pro software (Molecular Devices Corporation, Sun-
nyvale, CA). This calibration curve was used to determine
tPA activity in the various sample solutions from the
absorbance values. tPA activity is reported (in percent) as
the measured activity referenced by the standard activity at
the same tPA concentration; an activity of 100% means
that the sample tPA activity was equal to that of the stand-
ard. Twelve measurements were done for each sample age.
tPA activity versus sample age for the data Figure 1
tPA activity versus sample age for the data. The solid circles denote the average activity for all samples at the given sam-
ple age, and the error bars are the 95% confidence limits. The individual data points are the mean tPA activity values for a given 
concentration; the values are shown in the legend. Overall, there is no decline in tPA activity over time.Publish with BioMed Central    and   every 
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Figure 1 shows tPA activity versus sample age. The closed
circles with error bars are mean activity with 95% confi-
dence limits for all measurements at that sample age. The
individual data points are the mean activity at a given
sample age for a given concentration of tPA, as explicated
in the legend. There is no decrease of tPA activity with
sample age, and there is no definite trend in tPA activity as
a function of tPA concentration. These results are similar
to work by others [4,5] for shorter durations. Overall,
long-term low temperature storage of tPA preserves enzy-
matic activity and may be useful in preserving tPA solu-
tion for experimental use.
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